![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Current practice guidelines provide recommendations for the secondary prevention of coronary heart disease. Following the publication of clinical trials in recent years, this review will highlight some controversial issues: the role of angiotensin and aldosterone antagonists after acute myocardial infarction; the effects of angiotensin-converting enzyme inhibitors in patients with stable coronary heart disease and preserved left ventricular ejection fraction; high-intensity lowering of low-density lipoprotein cholesterol; use of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors in the elderly; and the targeting of high-density lipoprotein cholesterol with niacin.
Keywords
- 3-hydroxy-3-methyl-glutaryl coenzyme-A reductase inhibitors
- aldosterone antagonists
- angiotensin antagonists
- atorvastatin
- captopril
- coronary heart disease
- elderly
- eplerenone
- heart failure
- high-intensity lipid-lowering therapy
- left ventricular dysfunction
- left ventricular remodeling
- losartan
- niacin
- perindopril
- pravastatin
- ramipril
- simvastatin
- telmisartan
- trandolapril
- valsartan